Abstract:

Abstract: Cardiovascular diseases are the most common causes of death in patients with chronic kidney disease (CKD). It has been reported that fibroblast growth factor 23 (FGF23) was significantly higher in CKD, and correlated with the incidence of left ventricular hypertrophy (LVH) and cardiovascular events. The mechanism of FGF23 included activation of the renin-angiotensin-aldosterone system, promoting LVH without klotho and et al. Intervention therapy to reduce FGF23 remains inconclusive. Low phosphorus diet, phosphate binders and cinacalcet could reduce the level of FGF23 in CKD patients. However, its effectiveness still need further clinical studies to be evaluated